Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapy.

doi:10.1016/j.ejca.2021.06.024

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapy.

European journal of cancer (Oxford, England : 1990) - 1 Sept 2021

Tjokrowidjaja Angelina, Friedlander Michael, Lord Sarah J, Asher Rebecca, Rodrigues Manuel, Ledermann Jonathan A, Matulonis Ursula A, Oza Amit M, Bruchim Ilan, Huzarski Tomasz, Gourley Charlie, Harter Philipp, Vergote Ignace, Scott Clare L, Meier Werner, Shapira-Frommer Ronnie, Milenkova Tsveta, Pujade-Lauraine Eric, Gebski Val, Lee Chee K

Abstract excerpt

BACKGROUND: The impact of maintenance therapy with PARP inhibitors (PARPi) on progression-free survival (PFS) in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer (PSROC) varies widely. Individual prognostic factors do not reliably distinguish patients who progress early from those who have durable benefit. We developed and validated a prognostic nomogram to predict PFS in these...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Genes, BRCA1

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Genes, BRCA2

Share to Neoplasm Recurrence, Local

Share to Nomograms

Share to Ovarian Neoplasms

Share to Phthalazines

Share to Piperazines

Share to Progression-Free Survival

Source

Open in PubMed

Identifiers

PMID: 34293664
DOI: 10.1016/j.ejca.2021.06.024

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapy.PMID 34293664Read ↗

Molecular and clinical predictors of improvement in progression‐free survival with maintenance PARP inhibitor therapy in women with platinum‐sensitive, recurrent ovarian cancer: A meta‐analysisSemantic proximity Read ↗

Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.Semantic proximity Read ↗

Long-term progression-free survivors ("super responders") to olaparib maintenance in recurrent ovarian cancer: a multicenter real-world study (KCOG-G2101s).Semantic proximity Read ↗

Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genesSemantic proximity Read ↗

Bevacizumab or PARP-Inhibitors Maintenance Therapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis.Semantic proximity Read ↗

Second-line olaparib maintenance therapy is associated with poor response to subsequent chemotherapy in BRCA1/2-mutated epithelial ovarian cancer: A multicentre retrospective study.Semantic proximity Read ↗

Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial.Semantic proximity Read ↗

Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial.Semantic proximity Read ↗

Further Analyses Highlight Benefits of PARP Inhibitors As Frontline Maintenance in Ovarian Cancer.Semantic proximity Read ↗

Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trialSemantic proximity Read ↗

Primary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without BRCA Mutation.Semantic proximity Read ↗

Risk factors for progression or death after first-line platinum-based chemotherapy in real-world patients in the USA with ovarian cancer from 2011 to 2018.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.